# Copper Peptide Hair Growth: GHK-Cu in the Research Literature > Copper peptide hair growth research: a 45-man RCT found a 5-ALA + GHK complex raised hair count by up to 71.5 versus 9.6 for placebo, and a 2026 review maps GHK-Cu's VEGF and angiogenic follicle effects. The controlled hair-count data, the VEGF and angiogenesis mechanism, and the careful distinction between a GHK-containing combination and pure GHK-Cu. ## What the controlled hair data show Copper peptide hair growth research centers on GHK-Cu, and it has one genuinely controlled human signal worth stating precisely. In a 6-month randomized trial of 45 men with androgenetic alopecia (Norwood-Hamilton II-V), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide — the GHK-containing formulation ALAVAX — increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo, with statistical significance and no adverse events in any group [4]. A 2026 review of short peptides for hair loss cites that 45-patient trial as foundational peptide hair-loss evidence [12]. The important caveat is the formulation. The controlled gains came from a 5-ALA plus GHK combination applied to the scalp, not from pure GHK-Cu in isolation [4]. So the strongest evidence supports a GHK-containing topical, and mechanistic reviews then explain why a copper peptide would plausibly contribute — see the [copper peptide hair growth research](/hair-research) gathered below alongside the [GHK-Cu research findings](/research). ## Why a copper peptide acts on the follicle ### Do copper peptides stimulate hair growth? A 6-month RCT in 45 men with androgenetic alopecia found a 5-ALA + GHK complex increased hair count by 52.6 to 71.5 versus 9.6 for placebo [4], and a 2026 review attributes copper-peptide hair effects to VEGF-driven angiogenesis and follicular matrix turnover [12]. The mechanism is described as supplying blood flow and matrix support to the follicle rather than altering hormones. ### Does copper peptide regrow hair? Controlled human data come from a combination formulation (5-ALA + GHK) rather than pure GHK-Cu; that trial showed significant hair-count gains over placebo [4]. Mechanistic reviews describe angiogenic and anti-apoptotic follicle effects, with GHK-Cu increasing VEGF production in dermal fibroblasts and promoting follicular extracellular-matrix turnover [12]. ### Does copper peptide work for hair growth? Research reports positive follicle effects, with the strongest controlled signal from the 45-patient ALAVAX trial [4]. A 2026 short-peptide hair-loss review consolidates GHK-Cu's VEGF, angiogenesis and collagen/glycosaminoglycan rationale, describing stimulation of microvascular angiogenesis around the follicle [12]. ## Mechanism, timeline and the DHT question ### How long does GHK-Cu take to regrow hair? Research and product-context discussions suggest meaningful regrowth is typically observed over roughly three months of consistent use. The 45-patient ALAVAX trial measured hair-count gains across a 6-month protocol [4], so the controlled evidence is framed on a half-year timeline rather than a quick result. ### Is copper a DHT blocker? Copper-peptide hair effects in research are described as non-androgenic. An ionic-liquid microemulsion delivering 2% GHK-Cu drove follicles into anagen with no change in testosterone or estradiol, so the mechanism is angiogenic and follicular rather than DHT-blocking [12]. This is a meaningful distinction from hormone-pathway hair treatments: the copper peptide appears to support the follicle's environment, not suppress androgens. The broader follicle biology fits that picture. GHK-Cu promotes dermal-papilla-cell proliferation and inhibits their apoptosis in research models, and copper-peptide work reports extended anagen and faster re-entry from the resting telogen phase [12]. The 2026 review ties these together: VEGF production in dermal fibroblasts, microvascular angiogenesis, and collagen and glycosaminoglycan synthesis around the follicle [12]. As with the rest of this digest, the mechanism is well-described in preclinical and review literature, while the controlled human efficacy rests on the single combination trial [4]. ## Delivery: getting a copper peptide to the follicle Reaching the hair follicle is the same problem the skin literature faces, intensified by depth. Free GHK is highly hydrophilic, with a clogP of -2.24, which limits passive penetration through the stratum corneum [7]. That single number explains why the controlled hair trial used an applied complex rather than relying on a plain solution: the formulation has to carry the peptide past the skin barrier and down to the dermal papilla [4]. The enhancement strategies studied for skin carry over to the scalp. A human skin-penetration study quantified the route when copper is applied as the tripeptide: a permeability coefficient of 2.43 x 10^-4 cm/h, with 136.2 ug/cm^2 of copper permeating over 48 hours and 97 ug/cm^2 retained as a dermal depot [5]. A 2025 review evaluates palmitoylation (Pal-GHK, raising clogP to about 1.14) and microneedle pretreatment, the latter moving roughly 134 nmol of GHK through skin versus none through an intact barrier [7]. For follicle research specifically, an ionic-liquid microemulsion delivering 2% GHK-Cu was the vehicle that drove follicles into anagen [12]. The practical reading is that a copper peptide's hair effects depend as much on the delivery system as on the molecule. The dermal depot is the asset — copper held locally for prolonged availability rather than cleared in a sharp systemic peak [5]. ## Reading the hair evidence honestly The strongest claim the literature supports is specific and bounded: a GHK-containing topical produced statistically significant hair-count gains over placebo in 45 men across six months, with no adverse events in any group [4]. That is a genuine controlled result, and it is the foundation the 2026 short-peptide review builds its mechanistic case on [12]. The weaker points are worth naming with equal clarity. The trial tested a 5-ALA plus GHK combination, not pure GHK-Cu, so the contribution of the copper peptide alone is inferred from mechanism rather than isolated by design [4]. The angiogenic and anti-apoptotic follicle effects — VEGF upregulation, dermal-papilla proliferation, anagen extension — are drawn largely from preclinical and review literature [12]. And the broader gene-level and matrix findings that make GHK-Cu plausible for hair come from a body of work in which a large share of the foundational mechanistic literature originates from a single investigator and colleagues, which limits independent replication [2]. A curious reader can hold both halves at once: a real controlled signal, resting on a combination formulation, with a well-described but largely preclinical mechanism behind it. The [full GHK-Cu reference list](/references) gives every source. --- A misted reading-room for the GHK-Cu copper-tripeptide literature — each collagen, hair and wound-repair study held up to the light and cited at its source, the human-data gaps left translucent, with no clinic behind the glass and nothing here to dispense.